In silico homology modelling and identification of Tousled-like kinase 1 inhibitors for glioblastoma therapy via high throughput virtual screening protein-ligand docking
- Subject Areas
- Biochemistry, Bioinformatics, Computational Biology, Drugs and Devices, Oncology
- Tousled-like kinase 1, TLK1, GBM, Homology modelling, in silico high throughput virtual screening
- © 2016 Ibrahim et al.
- This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ Preprints) and either DOI or URL of the article must be cited.
- Cite this article
- 2016. In silico homology modelling and identification of Tousled-like kinase 1 inhibitors for glioblastoma therapy via high throughput virtual screening protein-ligand docking. PeerJ Preprints 4:e1582v3 https://doi.org/10.7287/peerj.preprints.1582v3
Background: Glioblastoma multiforme (GBM) is a grade IV brain tumor that arises from star-shaped glial cells supporting neural cells called astrocytes. The survival of GBM patients remains poor despite many specific molecular targets that have been developed and used for therapy. Tousled-like kinase 1 (TLK1), a serine-threonine kinase, was identified to be overexpressed in cancers such as GBM. TLK1 plays an important role in controlling chromosomal aggregation, cell survival and proliferation. In vitro studies suggested that TLK1 is a potential target for some cancers; hence, the identification of suitable molecular inhibitors for TLK1 is warranted as a new therapeutic agents in GBM. To date, there is no structure available for TLK1. In this study, we aimed to create a homology model of TLK1 and to identify suitable molecular inhibitors or compounds that are likely to bind and inhibit TLK1 activity via in silico high-throughput virtual screening (HTVS) protein-ligand docking. Methods: 3D homology models of TLK1 were derived from various servers including HOmology ModellER, i-Tasser, Psipred and Swiss Model. All models were evaluated using Swiss Model Q-Mean server. Only one model was selected for further analysis. Further validation was performed using PDBsum, 3d2go, ProSA, Procheck analysis and ERRAT. Energy minimization was performed using YASARA energy minimization server. Subsequently, HTVS was performed using Molegro Virtual Docker 6.0 and candidate ligands from ligand.info database. Ligand-docking procedures were analyzed at the putative catalytic site of TLK1. Drug-like molecules were filtered using FAF-Drugs3, which is an ADME-Tox filtering program. Results and conclusion: High quality homology models were obtained from the Aurora B kinase (PDB ID:4B8M) derived from Xenopus levias structure that share 33% sequence identity to TLK1. From the HTVS ligand-docking, two compounds were identified to be the potential inhibitors as it did not violate the Lipinski rule of five and the CNS-based filter as a potential drug-like molecule for GBM.
Spelling correction has been made on one of the author's name. References have been added and amended. Figure 1 and 4 have been enhanced.